Skip to the page
Get started – free

Data / Research funding / Gene Therapy Clinical Trials

Gene Therapy Clinical Trials: 125 NIH awards ($258.1M) to 58 organizations

125 NIH awards ($258.1M) in the NIH spending category Gene Therapy Clinical Trials, to 58 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on Gene Therapy Clinical TrialsWatch Gene Therapy Clinical Trials
Topic
NIH spending category

Awards

125 awards in the window.

AwardAgencyInstitute or divisionFiscal yearAmount in windowStartEndPrincipal investigatorSource
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseasesNIHNational Center for Advancing Translational Sciences2023 to 2025$26,526,303September 20, 2023July 31, 2027JIANG, YONG-HUIreporter.nih.gov
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantationNIHNational Institute of Allergy and Infectious Diseases2021 to 2025$14,843,451August 20, 2021May 31, 2028NAJI, ALIreporter.nih.gov
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.NIHNational Institute on Aging2022 to 2025$10,320,460February 15, 2022January 31, 2027AGADJANYAN, MICHAEL Greporter.nih.gov
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's AtaxiaNIHNational Heart, Lung, and Blood Institute2022 to 2024$5,884,638August 1, 2020August 31, 2025CRYSTAL, RONALD Greporter.nih.gov
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory AntibodiesNIHNational Heart, Lung, and Blood Institute2021 to 2023$4,780,411April 5, 2019March 31, 2026WILCOX, DAVID ALLENreporter.nih.gov
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's DiseaseNIHNational Institute on Aging2021 to 2024$4,266,904May 15, 2021April 30, 2027TUSZYNSKI, MARK H.reporter.nih.gov
NextGen - CRINIHNational Cancer Institute2022 to 2025$3,968,330June 1, 2025May 31, 2026BOLLARD, CATHERINE M.reporter.nih.gov
Human natural killer cells: Advancing biology and clinical applicationsNIHNational Cancer Institute2021 to 2025$3,769,374July 21, 2017June 30, 2032CALIGIURI, MICHAEL Areporter.nih.gov
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell diseaseNIHNational Heart, Lung, and Blood Institute2023 to 2025$3,710,340September 1, 2023August 31, 2028WEISS, MITCHELL Jreporter.nih.gov
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesNIHNational Cancer Institute2021 to 2025$3,687,540September 7, 2017June 30, 2032DIPERSIO, JOHN F.reporter.nih.gov
NGTC - UCLNIHNational Cancer Institute2022 to 2024$3,627,871June 1, 2024May 31, 2025PULE, MARTINreporter.nih.gov
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillationNIHNational Heart, Lung, and Blood Institute2022 to 2023$3,447,560September 15, 2021August 31, 2024DONAHUE, J KEVINreporter.nih.gov
Viral Gene Therapy for Menkes DiseaseNIHNational Institute of Neurological Disorders and Stroke2023 to 2025$3,444,962September 1, 2023June 30, 2027KALER, STEPHEN GERARDreporter.nih.gov
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vectorNIHNational Institute of Allergy and Infectious Diseases2021 to 2025$3,369,470July 7, 2016December 31, 2029WILLIAMS, DAVID Areporter.nih.gov
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline GliomasNIHNational Cancer Institute2021 to 2025$3,294,656August 6, 2021July 31, 2026MACKALL, CRYSTALreporter.nih.gov
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancerNIHNational Cancer Institute2022 to 2025$3,252,105April 1, 2022August 31, 2027POWELL, DANIEL J.reporter.nih.gov
IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trialsNIHNational Institute of Neurological Disorders and Stroke2024 to 2025$3,161,261August 1, 2024July 31, 2027STEDMAN, HANSELL Hreporter.nih.gov
CD28-KITv CAR T cells with PD-1 dominant negative receptorNIHNational Cancer Institute2024 to 2025$3,061,861March 1, 2024February 28, 2026ADUSUMILLI, PRASAD S.reporter.nih.gov
Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)NIHNational Institute of Neurological Disorders and Stroke2024 to 2025$2,992,236June 7, 2024May 31, 2026STEWART, CHARLES ANDREWreporter.nih.gov
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of GlioblastomaNIHNational Cancer Institute2021 to 2024$2,929,456August 1, 2020April 30, 2026BROWN, CHRISTINEreporter.nih.gov
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumorsNIHNational Cancer Institute2022 to 2025$2,924,883March 1, 2022February 28, 2027DERENZO, CHRISTOPHERreporter.nih.gov
Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid CytokinesNIHNational Cancer Institute2022 to 2025$2,917,317December 9, 2021November 30, 2026KENDERIAN, SAAD J.reporter.nih.gov
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatmentNIHNational Cancer Institute2024 to 2025$2,906,182September 9, 2024August 31, 2026POWELL, DANIEL J.reporter.nih.gov
Intratumor co-delivery of DNA and RNA to relieve cancer painNIHNational Institute of Dental & Craniofacial Research2021 to 2025$2,893,104January 8, 2021December 31, 2026SCHMIDT, BRIAN Lreporter.nih.gov
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticlesNIHNational Cancer Institute2022 to 2025$2,889,170September 1, 2022August 31, 2027SAYOUR, ELIASreporter.nih.gov
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disordersNIHNational Center for Advancing Translational Sciences2021 to 2022$2,786,444August 1, 2018July 31, 2024PARK, JULIE Rreporter.nih.gov
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian CancerNIHNational Cancer Institute2022 to 2025$2,785,861September 1, 2022June 30, 2027RODRIGUEZ-RODRIGUEZ, LORNAreporter.nih.gov
Next Generation GPC2-CARs for MedulloblastomaNIHNational Cancer Institute2024 to 2025$2,781,440September 13, 2024August 31, 2026MACKALL, CRYSTALreporter.nih.gov
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled ComparisonNIHNational Cancer Institute2022 to 2025$2,766,745July 1, 2022June 30, 2027JIM, HEATHER S.L.reporter.nih.gov
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell TherapyNIHNational Cancer Institute2023 to 2025$2,766,158September 1, 2023August 31, 2028HILL, JOSHUA AIDENreporter.nih.gov
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancerNIHNational Cancer Institute2023 to 2024$2,756,416August 9, 2023July 31, 2025MAUS, MARCELA VALDERRAMAreporter.nih.gov
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucelNIHNational Cancer Institute2021 to 2024$2,726,050September 1, 2020May 31, 2025MAUS, MARCELA VALDERRAMAreporter.nih.gov
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal CancerNIHNational Cancer Institute2023 to 2024$2,717,589September 19, 2023August 31, 2025YEE, CASSIANreporter.nih.gov
Next generation T cell therapies for mutant KRAS solid tumorsNIHNational Cancer Institute2023 to 2024$2,717,473September 1, 2023August 31, 2025CARRENO, BEATRIZ M.reporter.nih.gov
BAFF-R CAR T cell therapy for ALLNIHNational Cancer Institute2022 to 2025$2,663,058April 18, 2022March 31, 2027WANG, XIULIreporter.nih.gov
Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXTNIHNational Institute of Neurological Disorders and Stroke2024 to 2025$2,596,654August 15, 2025August 14, 2026CUDKOWICZ, MERIT Ereporter.nih.gov
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1NIHNational Institute of Allergy and Infectious Diseases2021 to 2023$2,576,704July 14, 2022June 30, 2025GOONETILLEKE, NILUreporter.nih.gov
Targeting B7-H3 in ovarian cancerNIHNational Cancer Institute2021 to 2025$2,515,188February 1, 2021January 31, 2027DOTTI, GIANPIETROreporter.nih.gov
Gene Therapy for Alpha 1-Antitrypsin DeficiencyNIHNational Heart, Lung, and Blood Institute2025$2,505,334May 15, 2024April 30, 2028CRYSTAL, RONALD Greporter.nih.gov
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System LymphomaNIHNational Cancer Institute2022 to 2025$2,499,820September 9, 2022August 31, 2028WANG, XIULIreporter.nih.gov
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumorsNIHNational Cancer Institute2022 to 2025$2,490,304January 17, 2022October 31, 2025HECZEY, ANDRAS A.reporter.nih.gov
Tailoring CAR T cell therapy for Hodgkin LymphomaNIHNational Cancer Institute2021 to 2024$2,475,444July 1, 2020June 30, 2026SAVOLDO, BARBARAreporter.nih.gov
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal CancerNIHNational Cancer Institute2025$2,270,520September 19, 2023August 31, 2028YEE, CASSIANreporter.nih.gov
Next generation T cell therapies for mutant KRAS solid tumorsNIHNational Cancer Institute2025$2,238,704September 1, 2025August 31, 2028CARRENO, BEATRIZ M.reporter.nih.gov
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trialNIHNational Institute of Neurological Disorders and Stroke2023 to 2025$2,149,389September 1, 2023August 31, 2027GRAY, STEVEN Jreporter.nih.gov
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesotheliomaNIHNational Cancer Institute2021 to 2024$2,116,571June 1, 2019May 31, 2025ADUSUMILLI, PRASAD S.reporter.nih.gov
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancerNIHNational Cancer Institute2025$2,054,733September 1, 2025August 31, 2028MAUS, MARCELA VALDERRAMAreporter.nih.gov
CAR T Cells for Advanced Thyroid CancerNIHNational Cancer Institute2021 to 2023$2,016,676April 23, 2021June 30, 2023JIN, MOONSOO M.reporter.nih.gov
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing processNIHNational Cancer Institute2022 to 2023$2,000,000September 1, 2022August 31, 2025DUKE, RICHARD Creporter.nih.gov
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipientsNIHNational Cancer Institute2024 to 2025$1,999,990September 20, 2024August 31, 2026BERTOLINO, ARTHUR Preporter.nih.gov
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLLNIHNational Cancer Institute2021 to 2022$1,998,672September 16, 2021August 31, 2023LITCHMAN, MANUELreporter.nih.gov
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant gliomaNIHNational Cancer Institute2021 to 2024$1,945,311January 1, 2019December 31, 2025BROWN, CHRISTINEreporter.nih.gov
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcomaNIHNational Cancer Institute2023 to 2025$1,938,900March 7, 2023February 29, 2028HEGDE, MEENAKSHI Greporter.nih.gov
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosisNIHNational Institute of Neurological Disorders and Stroke2021 to 2025$1,917,563March 1, 2021February 28, 2026JIANG, XUNTIANreporter.nih.gov
Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic MalignanciesNIHNational Cancer Institute2023 to 2025$1,860,326April 1, 2023March 31, 2028SIMPSON, RICHARD Jreporter.nih.gov
Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinicNIHNational Cancer Institute2025$1,847,485September 19, 2025August 31, 2029REZVANI, KATYreporter.nih.gov
Intravenous VSV virotherapy in lymphomaNIHNational Cancer Institute2023 to 2025$1,828,271May 11, 2023April 30, 2028PENG, KAH-WHYEreporter.nih.gov
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignanciesNIHNational Cancer Institute2023 to 2025$1,797,355July 21, 2023June 30, 2028VASU, SUMITHIRAreporter.nih.gov
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCLNIHNational Cancer Institute2023 to 2024$1,730,616September 9, 2020July 31, 2025DESAI, AVINASHreporter.nih.gov
"Blueprint of Life" Genomic Literacy Tool: An interactive to enhance genetic and genomic understanding with middle/high school students and their teachers through personal genetics and human diseaseNIHNational Institute of General Medical Sciences2021 to 2022$1,684,723September 1, 2019April 30, 2024SCUDERI, MASON EVANreporter.nih.gov
Immunoprevention and immunosurveillance of human non-viral cancersNIHNational Cancer Institute2021 to 2022$1,608,806August 1, 2016July 31, 2023FINN, OLIVERA Jreporter.nih.gov
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use DisordersNIHNational Institute on Alcohol Abuse and Alcoholism2021$1,500,000September 20, 2018August 31, 2022DUDEK, HENRYKreporter.nih.gov
Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)NIHNational Institute of Allergy and Infectious Diseases2021 to 2023$1,454,297August 5, 2014May 31, 2024VINCENTI, FLAVIOreporter.nih.gov
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell TherapyNIHNational Cancer Institute2024 to 2025$1,381,378August 1, 2024July 31, 2029OSWALD, LAURA B.reporter.nih.gov
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia ANIHNational Heart, Lung, and Blood Institute2021 to 2022$1,338,564January 10, 2018November 30, 2023DAVIDOFF, ANDREW Mreporter.nih.gov
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin LymphomaNIHNational Cancer Institute2024 to 2025$1,330,000August 1, 2024July 31, 2027VERA, JUAN FERNANDOreporter.nih.gov
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapyNIHNational Cancer Institute2025$1,313,567September 22, 2025August 31, 2027BERTOLINO, ARTHUR Preporter.nih.gov
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastomaNIHNational Cancer Institute2024 to 2025$1,305,576September 19, 2024August 31, 2029MAUS, MARCELA VALDERRAMAreporter.nih.gov
E7 TCR-T cell therapy for HPV-associated cancersNIHNational Cancer Institute2024 to 2025$1,269,979August 1, 2024July 31, 2028HINRICHS, CHRISTIANreporter.nih.gov
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerNIHNational Cancer Institute2024 to 2025$1,214,170February 1, 2024January 31, 2029LESINSKI, GREGORY B.reporter.nih.gov
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)NIHNational Institute of Neurological Disorders and Stroke2021$1,154,358April 15, 2020March 31, 2022KURTOGLU, METINreporter.nih.gov
Ultra-fast manufactured CAR-T therapyNIHNational Cancer Institute2025$1,125,000September 15, 2025August 31, 2027WALD, DAVIDreporter.nih.gov
A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphomaNIHNational Cancer Institute2025$1,124,607July 1, 2025June 30, 2027HEIN, SARAH MARIEreporter.nih.gov
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.NIHNational Cancer Institute2023 to 2025$1,093,197April 1, 2023March 31, 2028DAHER, MAYreporter.nih.gov
Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLLNIHNational Cancer Institute2024 to 2025$1,066,133April 1, 2024March 31, 2029HESS, BRIANreporter.nih.gov
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1NIHNational Heart, Lung, and Blood Institute2021 to 2025$1,047,558August 8, 2011June 30, 2031PIDALA, JOSEPH Areporter.nih.gov
From Research to Clinic: Addressing Ethical and Policy Challenges Facing the Gene Therapy EcosystemNIHNational Human Genome Research Institute2024 to 2025$1,045,585August 1, 2024May 31, 2027MASCHKE, KAREN JOANNreporter.nih.gov
Mechanisms of treatment failure in chimeric antigen receptor T cell therapyNIHNational Cancer Institute2021$1,032,791February 1, 2019March 31, 2022TILL, BRIANreporter.nih.gov
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLCNIHNational Cancer Institute2021 to 2024$1,028,396July 1, 2020June 30, 2026LISBERG, AARON ELLIOTTreporter.nih.gov
BMT Core- The Ohio State University blood and marrow transplant research consortiumNIHNational Heart, Lung, and Blood Institute2021 to 2025$1,022,473August 8, 2011June 30, 2031VASU, SUMITHIRAreporter.nih.gov
BMT Core- Medical College of WisconsinNIHNational Heart, Lung, and Blood Institute2021 to 2025$1,022,400July 27, 2017June 30, 2031SHAH, NIRAVreporter.nih.gov
Antisense therapy for the treatment of visual loss in Usher syndromeNIHNational Eye Institute2021 to 2023$1,016,887September 1, 2019June 30, 2025LENTZ, JENNIFER JEANreporter.nih.gov
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapyNIHNational Cancer Institute2025$992,425September 8, 2025August 31, 2027DEISHER, THERESA Areporter.nih.gov
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)NIHNational Cancer Institute2021$988,226August 1, 2018April 30, 2022STEWART, CHARLES ANDREWreporter.nih.gov
Mechanisms of treatment failure in chimeric antigen receptor T cell therapyNIHNational Cancer Institute2022 to 2023$979,067February 1, 2019July 31, 2025TILL, BRIANreporter.nih.gov
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine EfficacyNIHNational Cancer Institute2021 to 2022$965,975December 1, 2018July 31, 2023SAMPSON, JOHN H.reporter.nih.gov
Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesNIHNational Heart, Lung, and Blood Institute2021 to 2025$963,456August 8, 2011June 30, 2031PUSIC, ISKRAreporter.nih.gov
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell TherapyNIHNational Cancer Institute2022 to 2024$886,207July 20, 2022June 30, 2028YEE, CASSIANreporter.nih.gov
Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569NIHNational Cancer Institute2022$852,568September 1, 2022August 31, 2024ROBBINS, JOAN MARIEreporter.nih.gov
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumorsNIHNational Cancer Institute2021 to 2022$813,453August 15, 2018July 31, 2024ADUSUMILLI, PRASAD S.reporter.nih.gov
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgarisNIHNational Institute of Arthritis and Musculoskeletal and Skin Diseases2023 to 2024$798,009March 15, 2023June 30, 2024PAYNE, AIMEE Sreporter.nih.gov
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica NanoparticlesNIHNational Cancer Institute2023 to 2025$749,015December 1, 2023November 30, 2026BRADBURY, MICHELLE Sreporter.nih.gov
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic CancerNIHNational Cancer Institute2024 to 2025$741,150April 5, 2024March 31, 2029BASAR, RAFETreporter.nih.gov
CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHLNIHNational Cancer Institute2025$738,698December 1, 2024November 30, 2029WANG, XIULIreporter.nih.gov
DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung CancerNIHNational Cancer Institute2025$716,521August 25, 2025July 31, 2030SCHOENFELD, ADAM Jreporter.nih.gov
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR TherapiesNIHNational Cancer Institute2021 to 2024$675,912March 9, 2020February 28, 2025FRANK, MATTHEW J.reporter.nih.gov
Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome ModulationNIHNational Cancer Institute2025$667,533January 1, 2025December 31, 2029FACCIABENE, ANDREAreporter.nih.gov
Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene Therapy for GlioblastomaNIHNational Cancer Institute2021 to 2022$649,359June 1, 2019May 31, 2025GERSON, STANTON L.reporter.nih.gov
iC9-CAR.CSPG4 CAR-T Cells for Head and Neck Squamous Cell CarcinomaNIHNational Cancer Institute2025$627,456December 1, 2024November 30, 2029WEISS, JAREDreporter.nih.gov
CAR T Cells for Advanced Thyroid CancerNIHNational Cancer Institute2024$588,696February 2, 2024March 31, 2026JIN, MOONSOO M.reporter.nih.gov
Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)NIHNational Cancer Institute2024 to 2025$578,916September 1, 2024August 31, 2029TALLEUR, AIMEE C.reporter.nih.gov
Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)NIHNational Cancer Institute2025$553,167April 4, 2025March 31, 2030THOMPSON, ERICreporter.nih.gov
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapyNIHNational Cancer Institute2023 to 2025$539,966March 1, 2023February 29, 2028MYERS, REGINA Mreporter.nih.gov
BMT Core: Southeast Bone Marrow Transplant ConsortiumNIHNational Heart, Lung, and Blood Institute2024 to 2025$485,186August 15, 2024June 30, 2031WALLER, EDMUND Kreporter.nih.gov
B7-H3 CAR T cells following initial radiation for children and young adults with diffuse intrinsic pontine gliomaNIHNational Cancer Institute2025$456,414June 1, 2025April 30, 2030VITANZA, NICHOLAS Areporter.nih.gov
Gene Therapy for Alpha 1-Antitrypsin DeficiencyNIHNational Heart, Lung, and Blood Institute2024$422,895May 15, 2024April 30, 2025CRYSTAL, RONALD Greporter.nih.gov
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgarisNIHNational Institute of Arthritis and Musculoskeletal and Skin Diseases2024 to 2025$419,146March 15, 2023January 31, 2028PAYNE, AIMEE Sreporter.nih.gov
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillationNIHNational Heart, Lung, and Blood Institute2021$418,750September 15, 2021August 31, 2022DONAHUE, J KEVINreporter.nih.gov
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic AstrocytomaNIHNational Cancer Institute2023 to 2024$383,923July 14, 2023June 30, 2026SHAH, ASHISH HARISHreporter.nih.gov
Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell LymphomaNIHNational Cancer Institute2021$378,675May 1, 2021April 30, 2023STRATI, PAOLOreporter.nih.gov
Viral Gene Therapy for Menkes DiseaseNIHNational Institute of Neurological Disorders and Stroke2023$375,742September 1, 2023June 28, 2024KALER, STEPHEN GERARDreporter.nih.gov
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancerNIHNational Cancer Institute2021$373,073May 4, 2017August 31, 2023BAKKUM-GAMEZ, JAMIE Nreporter.nih.gov
ATP1A3-Related Disorders in Brazil: Natural History and Antisense Oligonucleotide Therapy DevelopmentNIHNational Institute of Neurological Disorders and Stroke2024$372,970September 17, 2024September 16, 2026MOCHIDA, GANESHWARAN HITOSHIreporter.nih.gov
Off-the-shelf engineered NK cells for the treatment of AMLNIHNational Cancer Institute2021$366,000December 20, 2016November 30, 2022REZVANI, KATYreporter.nih.gov
K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplantNIHNational Heart, Lung, and Blood Institute2024 to 2025$321,036August 15, 2024July 31, 2029CONWAY, SUSANreporter.nih.gov
Hypofractionated radiation in combination with B7-H3-CAR T cells for pediatric patients with relapsed/refractory sarcomasNIHNational Cancer Institute2025$289,937August 20, 2025July 31, 2030EPPERLY, REBECCA ANNEreporter.nih.gov
AAV-delivery of broadly neutralizing antibodies to augment ART-free control of HIV-1 in childrenNIHNational Institute of Allergy and Infectious Diseases2025$251,250August 5, 2025July 31, 2026LUZURIAGA, KATHERINE F.reporter.nih.gov
Infection prevention strategies after CAR-T cell therapyNIHNational Institute of Allergy and Infectious Diseases2025$205,901September 3, 2025August 31, 2030HILL, JOSHUA AIDENreporter.nih.gov
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell DiseaseNIHNational Heart, Lung, and Blood Institute2021$196,753September 5, 2017June 30, 2023WILLIAMS, DAVID Areporter.nih.gov
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid CancersNIHNational Cancer Institute2021$136,148April 1, 2018March 31, 2022HEDRICK, CATHERINE Creporter.nih.gov
Development and Validation of a Patient-Reported Measure Assessing Chimeric Antigen Receptor (CAR) T-Cell Therapy-Related Side EffectsNIHNational Cancer Institute2022 to 2023$134,000March 8, 2022February 28, 2025BARATA, ANNAreporter.nih.gov
Biostatistics Center for Lebers Hereditary Optic Neuropathy (LHON): Gene Therapy Clinical TrialNIHNational Eye Institute2021 to 2022$118,672April 1, 2014March 31, 2024O'BRIEN, ROBERT CHARLESreporter.nih.gov
Advancing Recognition and Personalized Genetic Medicine for MODY in a Multi-Ethnic US PopulationNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021$87,031July 1, 2017November 30, 2021NAYLOR, ROCHELLE NICOLEreporter.nih.gov
Lebers Hereditary Optic Neuropathy: Gene TherapyNIHNational Eye Institute2021 to 2022$2April 1, 2014March 31, 2025LAM, BYRON Lreporter.nih.gov
Development and Validation of a Patient-Reported Measure Assessing Chimeric Antigen Receptor (CAR) T-Cell Therapy-Related Side EffectsNIHNational Cancer Institute2022$1March 8, 2022March 9, 2022BARATA, ANNAreporter.nih.gov

Organizations

OrganizationPlaceNIH awardsNIH amountNSF awardsNSF amount
University of PennsylvaniaPhiladelphia, PA8$30.6 million0$0
Yale UniversityNew Haven, CT1$26.5 million0$0
Beckman Research Institute/city of HopeDuarte, CA7$17.3 million0$0
Weill Medical Coll of Cornell UnivNew York, NY5$11.6 million0$0
Massachusetts General HospitalBoston, MA6$11.6 million0$0
Institute for Molecular MedicineHuntington Beach, CA1$10.3 million0$0
University of TX MD Anderson Can CTRHouston, TX8$10.3 million0$0
ST. Jude Children's Research HospitalMemphis, TN5$8.8 million0$0
Univ of North Carolina Chapel HillChapel Hill, NC4$8.2 million0$0
Washington UniversitySaint Louis, MO4$7.1 million0$0
Stanford UniversityStanford, CA3$6.8 million0$0
Sloan-Kettering Inst Can ResearchNew York, NY4$6.7 million0$0
Medical College of WisconsinMilwaukee, WI2$5.8 million0$0
H. Lee Moffitt Cancer CTR & Res InstTampa, FL4$5.2 million0$0
Cartesian Therapeutics, Inc.Gaithersburg, MD3$5.1 million0$0
Mayo Clinic RochesterRochester, MN3$5.1 million0$0
Baylor College of MedicineHouston, TX2$4.4 million0$0
Children's Research InstituteWashington, DC2$4.3 million0$0
University of California, San DiegoLa Jolla, CA1$4.3 million0$0
Univ of Massachusetts Med SCH WorcesterWorcester, MA3$4.1 million0$0
Fred Hutchinson Cancer CenterSeattle, WA3$4 million0$0
Boston Children's HospitalBoston, MA3$3.9 million0$0
Columbia University Health SciencesNew York, NY2$3.9 million0$0
University College LondonLondon1$3.6 million0$0
Cytoagents, Inc.Pittsburgh, PA2$3.3 million0$0
Seattle Children's HospitalSeattle, WA2$3.2 million0$0
New York UniversityNew York, NY1$2.9 million0$0
University of FloridaGainesville, FL1$2.9 million0$0
Ohio State UniversityColumbus, OH2$2.8 million0$0
Ut Southwestern Medical CenterDallas, TX1$2.1 million0$0
Trampoline Pharma, Inc.Aurora, CO1$2 million0$0
Mustang Bio, Inc.Worcester, MA1$2 million0$0
University of ArizonaTucson, AZ1$1.9 million0$0
Actinium Pharmaceuticals, Inc.New York, NY1$1.7 million0$0
Emory UniversityAtlanta, GA2$1.7 million0$0
D'vinci Interactive, Inc.Hagerstown, MD1$1.7 million0$0
University of Pittsburgh at PittsburghPittsburgh, PA1$1.6 million0$0
Dicerna Pharmaceuticals, Inc.Cambridge, MA1$1.5 million0$0
University of California, San FranciscoSan Francisco, CA1$1.5 million0$0
Marker Therapeutics, Inc.Houston, TX1$1.3 million0$0
Rutgers Biomedical and Health SciencesNewark, NJ1$1.3 million0$0
Kure. Ai, Inc.Shaker Heights, OH1$1.1 million0$0
March Biosciences INCHouston, TX1$1.1 million0$0
Medical University of South CarolinaCharleston, SC1$1.1 million0$0
Hastings Center, Inc.Garrison, NY1$1 million0$0
Fred Hutchinson Cancer Research CenterSeattle, WA1$1 million0$0
University of California Los AngelesLos Angeles, CA1$1 million0$0
LSU Health Sciences CenterNew Orleans, LA1$1 million0$0
Avm Biotechnology, LLCSeattle, WA1$992,4250$0
Duke UniversityDurham, NC1$965,9750$0
Dnatrix, Inc.Carlsbad, CA1$852,5680$0
Case Western Reserve UniversityCleveland, OH1$649,3590$0
Methodist Hospital Research InstituteHouston, TX1$588,6960$0
Children's Hosp of PhiladelphiaPhiladelphia, PA1$539,9660$0
University of Miami School of MedicineCoral Gables, FL3$502,5970$0
Research Inst Nationwide Children's HospColumbus, OH1$375,7420$0
La Jolla Institute for ImmunologyLa Jolla, CA1$136,1480$0
University of ChicagoChicago, IL1$87,0310$0

Funding by fiscal year

Fiscal yearNIH awardsNIH amountNSF awardsNSF amount
202572$77,591,8390$0
202469$60,028,9870$0
202361$49,128,2360$0
202254$41,343,7950$0
202146$30,054,4770$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunityNumberAgencyListingClosesAward ceilingWhy it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)PA-24-254NIHJuly 12, 2027Not listedNotice number printed on 2 awards here
Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)PA-24-187NIHMay 7, 2027Not listedNotice number printed on 1 award here
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)PA-24-181NIHMay 8, 2027Not listedNotice number printed on 1 award here
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)PAR-27-089NIH93.395November 2, 2026Not listedSame assistance listing 93.395 as 63 awards here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)PAR-26-152NIH93.395November 11, 2026Not listedSame assistance listing 93.395 as 63 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)PAR-27-088NIH93.395November 20, 2026Not listedSame assistance listing 93.395 as 63 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)PAR-24-214NIH93.395January 7, 2027$375,000Same assistance listing 93.395 as 63 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)PAR-25-079NIH93.395January 7, 2027$500,000Same assistance listing 93.395 as 63 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)PAR-25-081NIH93.395January 7, 2027$499,999Same assistance listing 93.395 as 63 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)RFA-CA-27-005NIH93.395January 11, 2027$700,000Same assistance listing 93.395 as 63 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)PAR-27-009NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 63 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)RFA-CA-26-010NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 63 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)RFA-CA-27-003NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 63 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)PA-27-100NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 63 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)PA-27-102NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 63 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)RFA-CA-28-003NIH93.395June 11, 2027$600,000Same assistance listing 93.395 as 63 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)PA-24-253NIH93.395July 17, 2027Not listedSame assistance listing 93.395 as 63 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)PA-25-080NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 63 awards here
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)PAR-24-325NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 63 awards here
Investigator-Focused Award (Parent R35)PAR-28-037NIH93.395October 4, 2027Not listedSame assistance listing 93.395 as 63 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.